Atara Biotherapeutics, Inc. (LON:0HIY)

Market Cap	59.58M
Revenue (ttm)	137.71M
Net Income (ttm)	4.23M
Shares Out	n/a
EPS (ttm)	0.41
PE Ratio	14.09
Forward PE	9.05
Dividend	n/a
Ex-Dividend Date	n/a

Volume	105
Average Volume	358
Open	12.38
Previous Close	12.04
Day's Range	11.85 - 12.38
52-Week Range	5.00 - 18.80
Beta	n/a
RSI	50.84
Earnings Date	Nov 6, 2025

About Atara Biotherapeutics

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queenslan...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2012
• Employees: 153
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HIY

Financial Performance

In 2024, Atara Biotherapeutics's revenue was $128.94 million, an increase of 1404.02% compared to the previous year's $8.57 million. Losses were -$85.40 million, -69.07% less than in 2023.

Financial numbers in USD